NASDAQ:KALV

Finance·Mergers & Acquisitions·NASDAQ:KALV·News·Stock Market

KALV edges up with Chiesi deal price at $27, small gap left

KalVista Pharmaceuticals closed at $26.77 on Thursday, just below Chiesi Group’s $27 per share cash offer. Frazier Life Sciences-linked funds sold 3 million shares on May 19 at an average $26.78. Chiesi’s $1.9 billion tender offer expires June 10. The deal centers on EKTERLY, KalVista’s oral treatment for hereditary angioedema.

May 22, 2026

J Sainsbury Investment Narrative Shifts Amid Mixed Analyst Views
May 29, 2026, 10:46 PM EDT. The investment narrative for J Sainsbury (LSE:SBRY) is evolving with mixed analyst opinions. Fair value estimates slightly decreased from £3.55 to £3.48 per share amid varying target adjustments. Deutsche Bank and JPMorgan remain bullish, raising price targets to around £3.60 and £3.45, respectively, indicating potential upside. Conversely, Morgan Stanley, Goldman Sachs, and Citi adopt more cautious stances, highlighting competitive challenges. Sainsbury announced a £300 million share buyback plan through February 2027, supporting shareholder value. Adjustments include a slightly higher revenue growth forecast at 2.76%, a marginally lower net profit margin of 1.59%, and a discount rate revising to 9.00%. Investors can track developments via Simply Wall St's community and watchlists to gauge shifting market perspectives on the UK grocer's stock.